SNDX
Syndax Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology · US
$17.62
−0.34%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$17.64
From 52W high−29.94%
Volume5.17M
Market cap$1.57B
P/E (TTM)—
P/S (TTM)6.2x
Div yield—
Key dataSep 18, 2026
Open
$17.64
From 52W high
−29.94%
Volume
5.17M
Market cap
$1.57B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−11.9x
P/E (TTM)
—
RSI (14)
34.2
MomentumView details →
1D Return
−0.34%
YTD Return
−16.75%
SummaryUpdated Jun 1, 2026
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Waltham, Massachusetts. The company went public in March 2016 and has evolved from a research-focused organization into a commercial-stage company with two FDA-approved products launched in 2024. Syndax specializes in developing novel therapies for cancer treatment, with particular expertise in targeting specific protein interactions and immune system pathways that drive tumor growth and resistance to treatment.
Similar companies
Latest newsMore news →
Syndax Pharmaceuticals reported second quarter 2026 financial results, with total revenue of $73 million, a 92% year-over-year increase.47d agoSyndax Pharmaceuticals issued $250.0 million of 2.25% Convertible Senior Notes due 2031, with net proceeds of approximately $243.0 million for general corporate purposes.103d ago